David Jacobson is an Endocrinology/Metabolic physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2665 N Decatur Rd
Suite 520
Decatur, GA 300336149
Telephone
404-299-2223Registry record last updated 22 Dec 2009.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insulet CorporationProgram year20241 payment
- Medtronic, Inc.Program year20231 payment
- Abbott LaboratoriesProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
49.9%Insulin Analog23.3%Lantus Solostar22%Tresiba Flextouch U-10017%Novolog Flexpen16%Insulin Lispro Kwikpen U-1007%Humalog Kwikpen U-1007%Basaglar Kwikpen U-1007%Tresiba Flextouch U-2006%Fiasp Flextouch4%Lantus3%Toujeo Solostar2%Novolog2%Toujeo Max Solostar2%Humalog2%Insulin Lispro2%Admelog Solostar1%Insulin Aspart Flexpen1%Part D<11 patientsBiguanide (metformin)8.7%Metformin Hcl66%Metformin Hcl Er34%Part D≥101 patients+ 8 more classes in this area
Cardiovascular
24.5%Statin10.3%Atorvastatin Calcium65%Rosuvastatin Calcium25%Pravastatin Sodium5%Simvastatin5%Part D<11 patientsACE inhibitor4.1%Lisinopril69%Lisinopril-Hydrochlorothiazide31%Part D≥47 patients+ 6 more classes in this area
Hormonal (systemic)
23.6%l-Thyroxine22.2%Levothyroxine Sodium74%Synthroid24%Levoxyl1%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1.4%Methimazole100%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”